Sign inCreate account

Report workspace tools

NCT01976728COMPLETEDanonymous

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism

Sponsor

Source record

Ferring Pharmaceuticals

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Indication / condition

AI-normalized

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Intervention

Source record

Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)

Source & freshness

Source record

NCT ID

NCT01976728

Original source

ClinicalTrials.gov

Source last updated

Mar 03, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01976728

Title

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism

Sponsor

Ferring Pharmaceuticals

Status

COMPLETED

Phase

PHASE3

Condition raw

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Condition normalized

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Modality raw

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Modality normalized

small molecule

Target raw

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Target normalized

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Interventions

Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)

Public preview

Source record

This clinical trial evaluated the efficacy of three doses of Gonadorelin acetate administered via the OmniPod pump for ovulation induction in women with primary amenorrhea due to hypogonadotropic hypogonadism. The study was sponsored by Ferring Pharmaceuticals and completed in February 2018.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01976728

Status

COMPLETED

Phase

PHASE3

Sponsor

Ferring Pharmaceuticals

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the efficacy of three doses of Gonadorelin acetate administered via the OmniPod pump for ovulation induction in women with primary amenorrhea due to hypogonadotropic hypogonadism. The study was sponsored by Ferring Pharmaceuticals and completed in February 2018.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 03, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01976728

Indication

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Modality

small molecule

Target

Primary Amenorrhea With Hypogonadotropic Hypogonadism

Intervention

Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump, Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump, Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.